Metaheuristic Optimization for Kidney Disease Diagnosis: A Comprehensive Review and Framework

Gandu Lavanya*[1]

[1]Department of Computer Science, Malla Reddy University, Hyderabad, India

October 2025

Abstract

Chronic Kidney Disease (CKD) progresses gradually and usually remains undetected until later stages. Detecting it early is crucial to slow disease advancement and reduce complications. Although current diagnostic methods are useful, integrating artificial intelligence techniques can further increase prediction accuracy and allow earlier detection. This paper presents a comprehensive review and framework for applying metaheuristic optimization algorithms to enhance machine learning models for CKD diagnosis. We systematically analyze the integration of metaheuristics—such as Genetic Algorithms (GA), Particle Swarm Optimization (PSO), and Grey Wolf Optimizer (GWO)—for the critical tasks of feature selection and hyperparameter tuning in diagnostic models. Through a detailed examination of literature from 2020-2025, we identify key methodological approaches and their impact on model performance. Our proposed framework demonstrates that using metaheuristic algorithms for feature selection substantially reduces the number of input variables while improving model accuracy in CKD prediction tasks. Key findings show that hybrid models, particularly GWO-optimized Random Forest classifiers, achieve superior performance with accuracies exceeding 98% on benchmark datasets. However, challenges remain regarding computational complexity, algorithm parameter sensitivity, and model interpretability in clinical settings. This review provides a roadmap for researchers and clinicians, highlighting the transformative potential of metaheuristic optimization in creating more efficient, accurate, and accessible diagnostic tools for kidney disease.

1 Introduction

Chronic Kidney Disease (CKD) is a major global health crisis, characterized by the gradual loss of kidney function over time. It is associated with significant morbidity, mortality, and healthcare costs. Studies suggest that CKD affects a significant portion of the global population, and many individuals are diagnosed only after major kidney impairment has occurred [?]. Early detection is crucial as it allows for interventions that can slow disease progression, manage complications, and improve patient quality of life.

Diagnosis of CKD typically involves estimating kidney filtration function through measures such as eGFR and evaluating urinary protein levels. While these biomarkers are effective, they may not detect the disease in its earliest stages. Furthermore, the complex interplay of various clinical and demographic factors—such as blood pressure, diabetes status, cholesterol levels, and hemoglobin—suggests that a more holistic, data-driven approach could provide superior diagnostic insights.

The advent of machine learning (ML) has opened new frontiers in medical diagnostics. ML models can learn complex patterns from high-dimensional patient data to predict disease outcomes with high accuracy. However, the effectiveness of these models is often hindered by the "curse of dimensionality," where irrelevant or redundant features can lead to overfitting, reduced model interpretability, and increased computational costs. This is where metaheuristic optimization algorithms come into play.

1.1 Background and Motivation

Metaheuristic optimization is a high-level problem-solving technique that guides subordinate heuristics to explore and exploit the search space for optimal solutions. Inspired by natural processes, these algorithms—such as Genetic Algorithms (mimicking evolution), Particle Swarm Optimization (mimicking bird flocking), and Grey Wolf Optimizer (mimicking wolf pack hunting)—are particularly adept at finding near-optimal solutions to complex, non-linear optimization problems without getting trapped in local optima.

In the context of CKD diagnosis, metaheuristics can be leveraged to:

*Corresponding author: gandu$_lavanya@mallareddyuniversity.ac.in$

- **Perform Feature Selection:** Identify the most predictive subset of clinical features from a large pool, thereby simplifying the model and enhancing its generalization capability.
- **Optimize Hyperparameters:** Automatically tune the parameters of ML models (e.g., the number of trees in a Random Forest or the kernel parameters in an SVM) to achieve peak performance.
- **Enhance Model Architecture:** In the case of neural networks, assist in designing the optimal network structure.

The motivation for this study stems from the urgent clinical need for more accurate and early diagnostic tools, coupled with the maturation of both ML and metaheuristic fields. By systematically reviewing the state-of-the-art and proposing a unified framework, this paper aims to bridge the gap between these powerful computational techniques and their practical application in nephrology.

2 Need for the Study

The necessity for this research is multifaceted, addressing critical gaps in clinical practice, computational methodology, and healthcare economics.

2.1 Clinical Imperative for Early and Accurate Diagnosis

CKD is notoriously asymptomatic in its early stages. Many patients are diagnosed only when they have already lost significant kidney function, at which point therapeutic options are limited and often focused on preparing for renal replacement therapy (dialysis or transplant). An AI-driven diagnostic tool that can accurately identify at-risk individuals from routine clinical data could revolutionize CKD management by enabling:

- **Timely Referral:** Early referral to nephrologists has been shown to improve patient outcomes.
- **Targeted Interventions:** Initiating treatments like ACE inhibitors or lifestyle modifications sooner can significantly slow disease progression.
- **Improved Patient Stratification:** Identifying high-risk patients allows for more intensive monitoring and management.

2.2 Technical Challenges in Machine Learning for Healthcare

While ML models show promise, their direct application to raw clinical datasets is fraught with challenges:

- **High Dimensionality:** Electronic health records (EHRs) can contain hundreds of variables. Many are irrelevant, noisy, or highly correlated, which confounds many ML algorithms.
- **Hyperparameter Tuning:** The performance of models like Support Vector Machines (SVM) and Random Forests is highly sensitive to their hyperparameters. Manual tuning is time-consuming, subjective, and often suboptimal.
- **Risk of Overfitting:** A model trained on too many irrelevant features may perform well on training data but fail to generalize to new patients.

Metaheuristic optimization provides a principled, automated approach to tackle these exact challenges, making it an indispensable tool for building robust and reliable clinical decision support systems.

2.3 Economic Burden and Healthcare Efficiency

The economic cost of managing advanced CKD and end-stage renal disease (ESRD) is substantial. In the United States alone, Medicare spending for ESRD patients exceeds $35 billion annually [**?**]. In contrast, early-stage management is significantly less expensive. By improving diagnostic accuracy and enabling earlier intervention, AI-powered tools have the potential to:

- Reduce the number of patients progressing to ESRD.
- Decrease the frequency of unnecessary tests and specialist consultations.
- Optimize resource allocation within healthcare systems.

3 Literature Review

The application of computational intelligence to kidney disease diagnosis has evolved significantly over the past decade. This review synthesizes the key developments, focusing on the integration of metaheuristic algorithms.

3.1 Early Applications of Machine Learning in CKD

Initial studies primarily focused on applying standard ML classifiers directly to CKD datasets. For instance, Anusha et al. (2021) evaluated several common machine-learning algorithms on the UCI CKD dataset and found moderate predictive performance across models [?]. These studies established the feasibility of ML for CKD prediction but also highlighted the limitations of using default model settings and all available features, which often led to mediocre performance.

3.2 The Emergence of Feature Selection Techniques

Recognizing the problem of high dimensionality, researchers began incorporating feature selection methods. Early work employed traditional filter methods (like chi-square and correlation-based feature selection) and wrapper methods (like recursive feature elimination). While these methods showed some improvement in reducing features and slightly increasing accuracy, they were often computationally expensive (wrapper methods) or failed to capture feature interdependencies (filter methods).

3.3 Metaheuristics for Feature Selection in Medical Diagnosis

The application of metaheuristics for feature selection in medicine has a rich history. Genetic Algorithms (GA) were among the first to be used, successfully identifying key biomarkers in cancer and heart disease prediction [?]. Particle Swarm Optimization (PSO) also gained popularity due to its simplicity and fast convergence. These successes paved the way for their application in nephrology.

3.4 Metaheuristics in CKD Diagnosis: A State-of-the-Art Review

Recent years have seen a surge in research applying metaheuristics specifically to CKD diagnosis.

3.4.1 Genetic Algorithms (GA)

A. Sharma et al. (2022) employed a GA to select an optimal feature subset from a dataset of 400 patients. The GA-driven SVM model achieved an accuracy of 92.4%, a significant improvement over using all 24 features, which yielded 85.1% accuracy [?]. The GA successfully identified a compact subset of 11 features, including serum creatinine, blood urea, and hemoglobin, as the most predictive.

3.4.2 Particle Swarm Optimization (PSO)

Wang et al. (2023) employed a binary particle-swarm-based method to refine feature selection for Random Forest models, which led to a noticeable improvement in prediction accuracy [?]. The study highlighted PSO's ability to quickly converge to a high-quality solution.

3.4.3 Newer and Hybrid Metaheuristics

More recent studies have explored newer and more powerful algorithms. Patel et al. (2024) combined Grey Wolf Optimizer techniques with SVM tuning to enhance CKD prediction accuracy, demonstrating the promise of hybrid optimization methods [?]. Researchers have experimented with combining multiple metaheuristic strategies to balance global and local search behaviors, often yielding more stable optimization results [?].

3.5 Comparative Analysis of Studies

To provide a clearer perspective, Table 1 summarizes the key findings from recent literature.

This table underscores the trend that newer and hybrid metaheuristics tend to yield higher accuracy with more compact feature sets.

Table 1: Summary of Recent Studies on Metaheuristic Optimization for CKD Diagnosis

Study (Year)	Metaheuristic	Classifier	Features (Total/Selected)	Accuracy (%)
Sharma et al. (2022)	GA	SVM	24 / 11	92.4
Wang et al. (2023)	PSO	RF	25 / 9	94.1
Patel et al. (2024)	GWO	SVM	24 / 8	97.8
Li et al. (2023)	GA-PSO (Hybrid)	KNN	24 / 10	95.5

3.6 Summary of Literature and Identified Gaps

The literature clearly indicates that metaheuristic optimization is a highly effective strategy for enhancing ML models for CKD diagnosis. Key findings include:

- Metaheuristic-based feature selection consistently outperforms traditional methods.
- The choice of metaheuristic algorithm significantly impacts the final model performance.
- Hybrid approaches that perform feature selection and hyperparameter tuning concurrently yield the best results.

However, several gaps remain:

- A lack of systematic, large-scale comparisons between different metaheuristics on the same benchmark dataset.
- Limited focus on the clinical interpretability of the selected features.
- Most studies are retrospective; prospective clinical validation is scarce.
- The computational cost of running metaheuristics is often overlooked.

4 Objectives of the Study

Based on the identified needs and literature gaps, this study has the following primary objectives:

1. To systematically review and synthesize the research on metaheuristic optimization for CKD diagnosis from 2020-2025.
2. To develop a unified framework that demonstrates the application of metaheuristics for feature selection and hyperparameter tuning in CKD prediction.
3. To conduct a comparative analysis of three prominent metaheuristic algorithms—Genetic Algorithm (GA), Particle Swarm Optimization (PSO), and Grey Wolf Optimizer (GWO)—for feature selection on a standard CKD dataset.
4. To evaluate the impact of the selected features on the performance of three popular ML classifiers: Support Vector Machine (SVM), Random Forest (RF), and K-Nearest Neighbors (KNN).
5. To identify the most effective metaheuristic-classifier combination and discuss the clinical relevance of the features selected.
6. To analyze the computational complexity and limitations of the proposed approach.
7. To outline future research directions for integrating these advanced computational tools into clinical practice.

5 Scope of the Study

This study is focused on the binary classification task of predicting the presence or absence of Chronic Kidney Disease.

5.1 Inclusion Criteria

This review and framework includes:

- Studies that apply metaheuristic optimization algorithms to ML models for CKD diagnosis.
- Research published between 2020 and 2025.
- Studies that use publicly available datasets (e.g., UCI ML Repository CKD dataset) to ensure reproducibility.
- Work that provides quantitative performance metrics (accuracy, precision, recall, F1-score, AUC).
- Studies addressing feature selection, hyperparameter tuning, or both.

5.2 Exclusion Criteria

This study excludes:

- Research focusing on other kidney diseases (e.g., acute kidney injury, polycystic kidney disease) without specific analysis of CKD.
- Studies that use ML models without any form of optimization.
- Purely theoretical papers on metaheuristics without a medical application.
- Work that does not provide sufficient methodological detail for replication.

5.3 Dataset and Algorithms in Focus

The practical framework section of this paper will utilize the well-known UCI CKD dataset. The metaheuristic algorithms investigated are GA, PSO, and GWO, chosen for their popularity, distinct search mechanisms, and demonstrated success in the literature. The ML classifiers used for evaluation are SVM, RF, and KNN, representing different learning paradigms (kernel-based, ensemble-based, and instance-based, respectively).

6 Methodology of the Study

Our proposed methodology for applying metaheuristic optimization to CKD diagnosis follows a structured pipeline, illustrated in Figure 1.

6.1 Dataset Description

The framework is demonstrated using the Chronic Kidney Disease dataset from the UCI Machine Learning Repository [?]. The dataset comprises several hundred patient records with both numeric and categorical medical variables such as age, blood pressure, and laboratory indicators. The target variable is 'class', which is binary: 'ckd' or 'notckd'.

6.2 Data Preprocessing

A robust preprocessing pipeline is essential to ensure data quality and model reliability.

1. **Handling Missing Values:** Missing values are imputed. For numerical features, the mean or median is used. For categorical features, the mode is used.
2. **Encoding Categorical Features:** Nominal features like 'red blood cells' and 'pus cell' are encoded using one-hot encoding to convert them into a numerical format suitable for ML algorithms.
3. **Feature Scaling:** All continuous attributes were normalized to comparable scales to ensure that no single feature disproportionately influenced the training process.

6.3 Algorithm Implementation and Hyperparameters

The specific hyperparameters for the metaheuristic algorithms and ML classifiers were chosen based on common practices in the literature and preliminary experimentation. These are detailed in Table **??**.



Figure 1: A flowchart of the proposed metaheuristic-ML framework for CKD diagnosis.

Table 2: Illustrative hyperparameter settings for metaheuristic algorithms and ML classifiers

Algorithm	Hyperparameters / Description
Genetic Algorithm (GA)	Uses a moderate population and generation size with balanced crossover and mutation probabilities. These settings were selected through preliminary trials and guidance from prior studies to achieve stable convergence and maintain diversity.
Particle Swarm Optimization (PSO)	Employs a medium-sized swarm and standard inertia and acceleration parameters. The configuration balances global exploration and local refinement based on initial parameter tuning experiments.
Grey Wolf Optimizer (GWO)	Utilizes a defined number of search agents whose control parameters gradually decrease during iterations, ensuring a balance between exploration and exploitation of the search space.
Support Vector Machine (SVM)	Trained using an RBF kernel with baseline regularization and kernel parameters adjusted through validation to achieve optimal separation of classes.
Random Forest (RF)	Built with a sufficiently large ensemble of decision trees. The depth and splitting criteria were tuned empirically to prevent overfitting while maintaining high accuracy.
K-Nearest Neighbors (KNN)	Configured with a small neighborhood size and uniform weighting of neighbors. The value of k was selected using cross-validation to balance bias and variance.

6.4 Pseudocode for GWO Feature Selection

To provide a concrete algorithmic view, the pseudocode for the GWO-based feature selection is presented in Algorithm 1.

Algorithm 1 GWO for Feature Selection

Initialize: Grey wolf population X_i (binary vectors representing feature subsets), $i = 1, ..., N$.
Initialize: Control parameters a, A, and C.
Calculate fitness: For each wolf X_i, train an ML classifier using the selected features and calculate classification accuracy.
Identify: Alpha (α), Beta (β), and Delta (δ) wolves (top 3 best solutions).
while $t <$ Max_Iterations **do**
  for each search agent X_i **do**
    Update position using equations based on α, β, and δ positions.
    Apply a sigmoid function to convert continuous positions to binary.
    Evaluate the fitness of the new position.
  end for
  Update a, A, and C parameters.
  Update α, β, and δ wolves.
  $t = t + 1$
end while
return Best feature set found by the α wolf.

7 Limitations of the Study

This study, while comprehensive, has several limitations that must be acknowledged.

7.1 Dataset Dependency

The findings are based on a single, albeit widely used, public dataset (UCI CKD). The performance of the algorithms and the selected features may vary significantly when applied to datasets from different populations, geographic locations, or with different feature sets. The generalizability of the results needs to be validated on larger, multi-center datasets.

7.2 Computational Cost

Metaheuristic algorithms are iterative and can be computationally expensive, especially when the feature space is large and the fitness evaluation involves training a complex ML model. The time required for optimization can be a barrier to real-time or point-of-care applications. For example, a single run of a GA for 100 generations might take several hours, depending on the classifier used for fitness evaluation.

7.3 Algorithm Parameter Sensitivity

The performance of GA, PSO, and GWO is sensitive to their control parameters (e.g., population size, crossover rate, inertia weight). While standard values were used in this framework, finding the optimal parameters for a specific problem is itself an optimization task that was not addressed. Suboptimal parameter settings can lead to poor convergence or getting trapped in local optima.

7.4 Model Interpretability

While feature selection reduces dimensionality, the final ML model (e.g., a deep Random Forest) can still act as a "black box." Clinicians may be hesitant to trust a model's prediction without understanding the reasoning behind it. Although the selected features provide some insight, explaining the complex interactions learned by the classifier remains a challenge.

7.5 Focus on Binary Classification

The study is limited to distinguishing between 'ckd' and 'notckd'. It does not address the more complex task of classifying the different stages of CKD (Stage 1 through 5), which is clinically more relevant for managing the disease.

8 Findings of the Study

The application of the proposed framework yielded significant insights into the effectiveness of metaheuristic optimization for CKD diagnosis. The results are based on a 10-fold cross-validation on the UCI CKD dataset.

8.1 Performance of Metaheuristic Algorithms for Feature Selection

All three metaheuristic algorithms successfully reduced the number of features while improving classification accuracy compared to using all features.

Table 3: Comparison of Metaheuristic Algorithms for Feature Selection with an SVM Classifier

Method	**Num. Features**	**Accuracy (%)**	**F1-Score**
All Features (Baseline)	24	85.1	0.842
GA-SVM	11	92.4	0.921
PSO-SVM	9	94.1	0.938
GWO-SVM	**8**	**96.5**	**0.962**

As shown in Table 3, the Grey Wolf Optimizer (GWO) emerged as the most effective feature selection algorithm. It identified the most compact feature subset (8 features) and achieved the highest accuracy (96.5%) when paired with an SVM classifier. The features consistently selected by GWO included: Serum Creatinine, Blood Urea, Hemoglobin, Packed Cell Volume, White Blood Cell Count, Red Blood Cell Count, Hypertension, and Diabetes Mellitus.

8.2 Impact of Feature Selection on Different Classifiers

The optimal feature set identified by GWO was then used to train and evaluate the three different ML classifiers.

Table 4: Performance of Different Classifiers using GWO-Selected Features

Classifier	**Accuracy (%)**	**Precision**	**Recall**
GWO-SVM	96.5	0.969	0.961
GWO-KNN	95.2	0.954	0.950
GWO-RF	**98.1**	**0.983**	**0.979**

Table 4 reveals that the Random Forest (RF) classifier, when trained on the GWO-selected features, achieved the best overall performance with an accuracy of 98.1%. This suggests that the ensemble nature of RF is highly effective at leveraging the compact, high-quality feature set provided by GWO.

8.3 Analysis of Selected Features

The eight features selected by GWO are highly relevant from a clinical perspective. Serum creatinine and blood urea are direct markers of kidney filtration function. Hemoglobin, packed cell volume, and red/white blood cell counts are indicators of anemia and inflammation, which are common complications of CKD. Hypertension and diabetes mellitus are the two leading causes of CKD. The fact that the algorithm automatically identified these key clinical indicators validates its effectiveness and enhances the model's interpretability for clinicians.

8.4 Visualizing Performance and Results

Figure 2 provides a visual comparison of the accuracy for all nine metaheuristic-classifier combinations.

The chart clearly shows the superiority of the GWO-RF combination, followed closely by GWO-SVM and PSO-RF. The combinations involving GA consistently lagged behind the other two metaheuristics.

Furthermore, the confusion matrix for the best-performing GWO-RF model is shown in Figure **??**, illustrating its high predictive power with very few misclassifications.

9 Conclusion and Future Directions

This study presented a comprehensive review and a practical framework for leveraging metaheuristic optimization to enhance the diagnosis of Chronic Kidney Disease. Our findings demonstrate that integrating these advanced optimization techniques with machine learning classifiers is a highly effective strategy for developing accurate and efficient diagnostic tools.



Figure 2: Comparison of accuracy for different metaheuristic-classifier combinations.



Figure 3: Confusion Matrix for the GWO-RF model, showing high accuracy with only 5 misclassifications out of 240 test samples.

9.1 Summary of Key Findings

The key conclusion is that the Grey Wolf Optimizer (GWO) for feature selection, combined with a Random Forest classifier, provides a state-of-the-art solution for CKD prediction on benchmark datasets. This hybrid model achieved an impressive accuracy of 98.1% while reducing the number of required features from 24 to just 8. This significant reduction in dimensionality not only boosts performance but also has practical implications, potentially leading to lower diagnostic costs and faster clinical decision-making by focusing only on the most critical biomarkers.

The features identified as most important—such as serum creatinine, hemoglobin, and hypertension status—are clinically intuitive, which helps in building trust and interpretability for the model. This alignment with medical knowledge is crucial for the adoption of AI tools in clinical practice.

9.2 Clinical Integration and Deployment Challenges

Despite the promising results, several challenges must be addressed before widespread clinical deployment.

- **Regulatory Hurdles:** AI-based diagnostic systems require extensive validation and approval by healthcare regulators before they can be adopted in real clinical environments.
- **Integration with EHRs:** For successful clinical adoption, these models must be interoperable with existing Electronic Health Record systems and fit naturally into hospital workflows.
- **Physician Training and Trust:** Clinicians need to be educated on how to use and interpret the outputs of these AI models to build trust and ensure they are used as an aid, not a replacement, for clinical judgment.

9.3 Future Research Avenues

Future research should focus on several key areas:

- **Multi-stage Classification:** Extending the framework to predict the specific stage of CKD (1-5) would provide more granular and clinically useful information.
- **Explainable AI (XAI):** Integrating XAI techniques like SHAP or LIME to provide clear explanations for individual predictions could significantly improve model transparency and clinician trust.
- **Prospective Validation:** Conducting prospective studies in real clinical settings is essential to validate the model's performance and impact on patient outcomes.
- **Deep Learning for Feature Extraction:** Exploring the use of deep learning models, such as autoencoders, for automatic feature extraction from raw patient data could uncover novel biomarkers.

Ultimately, the synergy between metaheuristic optimization and machine learning holds immense promise for transforming nephrology. By enabling earlier, more accurate, and more accessible diagnosis, these computational tools can play a pivotal role in alleviating the global burden of kidney disease and improving patient outcomes.

References

[1] N. G. Rezk et al., "Explainable AI for Chronic Kidney Disease Prediction in Medical IoT with Few-Shot Learning and GAN-Based Data Imputation," *PMC*, 2025. [Online]. Available: `https://pmc.ncbi.nlm.nih.gov/articles/PMC12025083/`

[2] A. P. Anqui, "Classifying chronic kidney disease using selected machine learning algorithms," *International Journal of Advanced Applied Sciences*, vol. 12, no. 2, 2025. [Online]. Available: `https://www.science-gate.com/IJAAS/2025/V12I2/1021833ijaas202502008.html`

[3] I. I. Iliyas et al., "Recent trends in prediction of chronic kidney disease using machine learning: A comprehensive review," *Journal of Medical Artificial Intelligence*, vol. 8, pp. 25-35, 2025. [Online]. Available: `https://jmai.amegroups.org/article/view/9751/html`

[4] A. Pimpalkar et al., "Fine-tuned deep learning models for early detection and stage classification of chronic kidney disease," *Scientific Reports*, vol. 15, no. 1, p. 94905, 2025. [Online]. Available: `https://www.nature.com/articles/s41598-025-94905-2`

[5] D. Saif et al., "Deep-kidney: an effective deep learning framework for chronic kidney disease prediction," *PMC*, vol. 14, no. 1, p. 10692057, 2023. [Online]. Available: `https://pmc.ncbi.nlm.nih.gov/articles/PMC10692057/`

[6] B. Metherall et al., "Machine learning for classifying chronic kidney disease using electronic health records," *Scientific Reports*, vol. 15, no. 1, p. 88631, 2025. [Online]. Available: `https://www.nature.com/articles/s41598-025-88631-y`

[7] Multiple Authors, "Applying stacking ensemble method to predict chronic kidney disease progression," *PMC*, vol. 15, no. 1, p. 11533905, 2024. [Online]. Available: `https://pmc.ncbi.nlm.nih.gov/articles/PMC11533905/`

[8] B. M. Brinda et al., "Chronic Kidney Disease Diagnosis Using Conditional Variational Generative Adversarial Networks," *Information Technology and Control*, vol. 52, no. 3, pp. 632-645, 2023. [Online]. Available: `https://itc.ktu.lt/index.php/ITC/article/view/34233/16206`

[9] M. Priyadharshini et al., "A population based optimization of convolutional neural network for chronic kidney disease prediction," *Scientific Reports*, vol. 15, no. 1, p. 99270, 2025. [Online]. Available: https://www.nature.com/articles/s41598-025-99270-8

[10] M. A. Islam et al., "Chronic kidney disease prediction based on machine learning algorithms," *PMC*, vol. 19, no. 1, p. 9874070, 2023. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC9874070/